The HEXA Knockout NCI-H1975 Polyclonal Cells are a human lung adenocarcinoma cell model engineered by CRISPR/Cas9-mediated disruption of the HEXA gene. This product consists of a polyclonal population of NCI-H1975 cells carrying targeted gene disruptions, providing a loss-of-function model for studying HEXA-dependent processes. Unlike clonal isolates, these polyclonal knockout cells represent a heterogeneous mixture of edited alleles, enabling robust and reproducible analysis of gene function without the confounding effects of clonal variation. This format is particularly suited for applications requiring stable gene inactivation in a physiologically relevant cancer cell background, allowing researchers to dissect lysosomal enzyme roles in tumor biology and neurodegenerative disease mechanisms.
The host cell line, NCI-H1975, is a widely used human non-small cell lung carcinoma (NSCLC) model derived from a female patient. These cells harbor activating EGFR L858R and T790M mutations, rendering them a valuable system for investigating EGFR-targeted therapies and resistance mechanisms. As an adherent epithelial line, NCI-H1975 maintains key characteristics of lung adenocarcinoma, including anchorage-dependent growth and oncogenic signaling dependencies. The EGFR T790M mutation, in particular, confers resistance to first-generation tyrosine kinase inhibitors, making this line a cornerstone for studying acquired drug resistance. Integrating HEXA knockout into this background provides a unique opportunity to examine how lysosomal dysfunction intersects with oncogenic signaling pathways.
HEXA encodes the alpha subunit of the lysosomal ??-hexosaminidase A enzyme, which together with the HEXB-encoded beta subunit forms a heterodimeric complex responsible for cleaving terminal non-reducing N-acetyl-D-hexosamine residues from GM2 gangliosides. This catabolic step requires the GM2A activator protein for substrate presentation and produces GM3 ganglioside as a downstream intermediate. Transcriptional regulation of HEXA and other lysosomal genes is controlled by TFEB, a master regulator of lysosomal biogenesis that responds to cellular stress and lysosomal dysfunction. HEXA function is intertwined with lysosomal membrane stability, mediated in part by LAMP1 and LAMP2 proteins. Dysregulation of this pathway results in pathological accumulation of GM2, the hallmark of Tay-Sachs disease and related GM2 gangliosidoses.
Introducing HEXA knockout into the NCI-H1975 background creates a unique platform to explore intersections between oncogenic signaling and lysosomal storage pathology. Given the host line’s dependence on EGFR signaling, researchers can investigate whether GM2 accumulation alters endolysosomal trafficking, autophagy, or drug sensitivity in lung adenocarcinoma. This model bridges cancer biology and neurodegenerative lysosomal storage disorder research, offering insights into how lysosomal dysfunction may influence tumor cell behavior. The presence of EGFR mutations further allows for the study of reciprocal interactions between EGFR-driven proliferation and lysosomal catabolic processes, potentially revealing vulnerabilities that could be exploited therapeutically in NSCLC.
This HEXA knockout polyclonal population is suited for modeling Tay-Sachs disease, evaluating enzyme replacement therapies, and screening small molecules for pharmacological chaperone activity. Researchers can validate HEXA loss by hexosaminidase activity assays, western blotting for HEXA and HEXB, and RT-qPCR of lysosomal genes. GM2 accumulation can be monitored by mass spectrometry or immunofluorescence, while LysoTracker staining assesses lysosomal compartment changes. Additionally, this model can be used in gene therapy studies aiming to restore HEXA function. For further information, please contact Ascent Research.
